Tuesday, November 16, 2004 1:52:57 AM
Wednesday, November 03, 2004 9:41:54 AM ET
First Albany
NEW YORK, November 3 (newratings.com) - Analysts at First Albany reiterate their "buy" rating on Able Laboratories (ABRX.NAS). The target price has been raised from $25 to $27.
Most popular stories:
Advanced Micro Devices "market outperform," target price raised 11/15/04
MediGene "buy," fair value raised 11/15/04
Boeing unveils cargo 777 airplane model 11/15/04
Medco Health Solutions upgraded to "buy" 11/15/04
XCYTE Therapies upgraded to "outperform" - update 11/15/04
more...
In a research note published this morning, the analysts mention that the company reported its Q3 EPS marginally ahead of the estimates and the consensus. The upside during the quarter was driven by higher-than-expected sales from Able Laboratories' new products, the analysts say. The company is expected to file 15-to-20 ANDAs by 1H05, First Albany adds.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM